Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
JDP2 antisense RNA 1 (JDP2-AS1) is presumed to be a long non-coding RNA transcribed from the opposite strand of the JDP2 locus. Very limited published research or drug discovery information is available for JDP2-AS1 as a distinct molecule. The primary well-characterized entity at this locus is the Jun dimerization protein 2 (JDP2), a transcription factor belonging to the AP-1 family, which acts as a heterodimerization partner for c-Jun, plays a role in gene regulation, cell differentiation, apoptosis, and certain disease processes including cancer and bone homeostasis. There is no evidence to support JDP2-AS1 as a validated or characterized therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on JDP2 antisense RNA 1 (JDP2-AS1).